Clinical Trial Update: Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating nicotinamide riboside for Moyamoya-like cerebrovascular disease in Smooth Muscle Dysfunction Syndrome (SMDS) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Moyamoya Disease
• Smooth Muscle Dysfunction Syndrome

Drugs mentioned

• Nicotinamide Riboside (nicotinamide riboside)

Snippet

Sponsor: The University of Texas Health Science Center, Houston | Conditions: Smooth Muscle Dysfunction Syndrome (SMDS) | Phase 1 | Status: RECRUITING